Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

In vitro diagnostics firms terminate their Dec. 22 merger agreement. "In response to disappointing test results and its loss of collaborative partner support," Cortech "has substantially reduced its staffing and has effectively discontinued all internal research and development activities" and is "currently evaluating its strategic alternatives," Cortech states. Valued at about $18.7 mil., the acquisition of BioStar would have shifted Cortech's focus toward point-of-care diagnostics ("The Gray Sheet" Jan. 5, I&W-3)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts